Tips from Other Journals

Individualizing Nicotine Replacement Therapy



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2005 Feb 1;71(3):570-573.

Nicotine replacement therapy can help motivated patients stop smoking, but long-term abstinence is a more difficult goal. Patient preference, which often guides the choice of a particular type of treatment, does not improve the outcome of nicotine replacement therapy. Lerman and associates compared the efficacy of transdermal nicotine with nicotine nasal spray to identify patient characteristics that might predict treatment outcomes.

These two forms of nicotine replacement therapy were chosen because of their differing pharmacodynamics, with transdermal preparations offering a slow nicotine administration with a four- to six-hour steady state, while the nasal spray more closely mimics the immediate nicotine peak achieved with smoking cigarettes. Healthy, treatment-seeking smokers were enrolled in a randomized, open-label, eight-week clinical trial of transdermal nicotine (Nicoderm CQ, 21 mg, tapering after four weeks) versus nicotine nasal spray (Nicotrol, 1.0-mg dose given as 0.5-mg spray in each nostril with a maximum of five doses per hour, tapered after four weeks) for smoking cessation. All patients received seven sessions of standarized behavioral group therapy. Smoking status was assessed by telephone, first at the end of treatment (eight weeks after the target quit date), and again six months after the target quit date.

The transdermal nicotine group achieved a higher prolonged abstinence rate through the end of treatment (62.5 percent) compared with the nicotine nasal spray group (44.5 percent). Six months later, abstinence rates were not significantly different in the two groups (28.5 versus 24.5 percent). No serious adverse events were reported. White, nonobese smokers with low to moderate levels of nicotine dependence had a better response to transdermal nicotine.

The authors conclude that pretreatment patient characteristics may help in the individualization of nicotine replacement therapy. Transdermal nicotine is a more effective treatment in white, nonobese smokers who have low nicotine dependence, while nicotine nasal spray is more beneficial in obese smokers who are highly nicotine dependent and members of minority groups.

Lerman C, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence. Ann Intern Med. March 16, 2004;140:426–33.



Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article